Dynamic Capital Management Ltd Boosts Position in Vertex Pharmaceuticals Incorporated (VRTX)

Dynamic Capital Management Ltd raised its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 53.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 39,614 shares of the pharmaceutical company’s stock after buying an additional 13,853 shares during the period. Dynamic Capital Management Ltd’s holdings in Vertex Pharmaceuticals were worth $4,332,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Franklin Resources Inc. boosted its position in shares of Vertex Pharmaceuticals by 4.6% in the fourth quarter. Franklin Resources Inc. now owns 1,450,278 shares of the pharmaceutical company’s stock valued at $106,842,000 after buying an additional 64,159 shares during the period. A.R.T. Advisors LLC boosted its position in shares of Vertex Pharmaceuticals by 229.1% in the fourth quarter. A.R.T. Advisors LLC now owns 36,200 shares of the pharmaceutical company’s stock valued at $2,666,000 after buying an additional 25,200 shares during the period. Arrowpoint Asset Management LLC boosted its position in shares of Vertex Pharmaceuticals by 35.1% in the fourth quarter. Arrowpoint Asset Management LLC now owns 5,250 shares of the pharmaceutical company’s stock valued at $387,000 after buying an additional 1,364 shares during the period. Credit Agricole S A boosted its position in shares of Vertex Pharmaceuticals by 22.3% in the fourth quarter. Credit Agricole S A now owns 74,409 shares of the pharmaceutical company’s stock valued at $5,482,000 after buying an additional 13,591 shares during the period. Finally, Trexquant Investment LP acquired a new position in shares of Vertex Pharmaceuticals during the fourth quarter valued at about $258,000. 94.18% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) traded up 0.617% during trading on Tuesday, reaching $126.355. 1,344,956 shares of the company were exchanged. The firm has a market capitalization of $31.47 billion, a PE ratio of 176.227 and a beta of 1.65. Vertex Pharmaceuticals Incorporated has a 12 month low of $71.46 and a 12 month high of $130.69. The stock has a 50 day moving average price of $120.51 and a 200 day moving average price of $98.35.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Thursday, April 27th. The pharmaceutical company reported $0.13 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.04 by $0.09. Vertex Pharmaceuticals had a net margin of 8.64% and a return on equity of 3.00%. The firm had revenue of $714.72 million during the quarter, compared to the consensus estimate of $692.64 million. During the same period last year, the firm posted $0.09 EPS. The firm’s revenue for the quarter was up 79.5% on a year-over-year basis. On average, analysts expect that Vertex Pharmaceuticals Incorporated will post $1.66 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.tickerreport.com/banking-finance/2656279/dynamic-capital-management-ltd-boosts-position-in-vertex-pharmaceuticals-incorporated-vrtx.html.

Several research analysts recently issued reports on the stock. CIBC raised shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Friday, June 2nd. Oppenheimer Holdings, Inc. raised shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $150.00 target price for the company in a report on Friday, June 2nd. Jefferies Group LLC reissued a “buy” rating and set a $126.00 target price on shares of Vertex Pharmaceuticals in a report on Friday, June 9th. TheStreet raised shares of Vertex Pharmaceuticals from a “c” rating to a “b-” rating in a report on Tuesday, May 2nd. Finally, Vetr raised shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and set a $119.50 target price for the company in a report on Tuesday, May 30th. Nine equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $117.02.

In other Vertex Pharmaceuticals news, CEO Jeffrey M. Leiden sold 157,200 shares of the firm’s stock in a transaction dated Friday, April 28th. The shares were sold at an average price of $119.50, for a total transaction of $18,785,400.00. Following the completion of the transaction, the chief executive officer now directly owns 395,152 shares in the company, valued at approximately $47,220,664. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP David Altshuler sold 7,500 shares of the firm’s stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $130.00, for a total transaction of $975,000.00. Following the transaction, the executive vice president now owns 113,511 shares of the company’s stock, valued at $14,756,430. The disclosure for this sale can be found here. Insiders have sold a total of 499,175 shares of company stock valued at $60,610,079 over the last 90 days. 1.90% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:VRTX”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Blue Apron Filed Thursday for Public Offering
Blue Apron Filed Thursday for Public Offering
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Large Auto Lender Checked Just 8% of Incomes for Applicants
Large Auto Lender Checked Just 8% of Incomes for Applicants


Leave a Reply

© 2006-2017 Ticker Report. Google+.